NUCLIDIUM Announces Issuance of New U.S. Patent Covering its 61Cu-based Radiodiagnostic Program for PSMA-positive Prostate Cancer
NUCLIDIUM was featured by BioCentury in an Emerging Company Profile highlighting the company’s unique copper-based approach in targeted radiotheranostic development